Immunotherapy is being intensively developed for the treatment of gliomas including the use of therapeutic vaccines, immune checkpoint inhibitors, and adoptive cell transfer. However, these strategies have not yet been proven to significantly impact patient survival. One of the major obstacles to effective anti-tumor immunity in gliomas is the local immunosuppression induced by the tumor and by the localization of gliomas in the central nervous system.
In order to improve current immunotherapies, this Research Topic aims to improve our understanding of how to manipulate innate immune cells for optimal activation of adaptive immune responses, and how to modulate local immunosuppressive cells and the local immunosuppressive milieu to promote effector cell survival and effector function. Answering these questions will benefit from the use of relevant mouse models of gliomas.
We, therefore, welcome the submission of Original Research Articles, Reviews, and Expert Opinions on themes including, but not limited to :
· Eliciting innate immunity to activate adaptive immune responses
· Reprogramming of myeloid cells into a pro-inflammatory phenotype
· Hypoxia and metabolic limitations
· Effector cell survival in the tumor microenvironment
· Syngeneic, xenogeneic and humanized mouse models
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Immunotherapy is being intensively developed for the treatment of gliomas including the use of therapeutic vaccines, immune checkpoint inhibitors, and adoptive cell transfer. However, these strategies have not yet been proven to significantly impact patient survival. One of the major obstacles to effective anti-tumor immunity in gliomas is the local immunosuppression induced by the tumor and by the localization of gliomas in the central nervous system.
In order to improve current immunotherapies, this Research Topic aims to improve our understanding of how to manipulate innate immune cells for optimal activation of adaptive immune responses, and how to modulate local immunosuppressive cells and the local immunosuppressive milieu to promote effector cell survival and effector function. Answering these questions will benefit from the use of relevant mouse models of gliomas.
We, therefore, welcome the submission of Original Research Articles, Reviews, and Expert Opinions on themes including, but not limited to :
· Eliciting innate immunity to activate adaptive immune responses
· Reprogramming of myeloid cells into a pro-inflammatory phenotype
· Hypoxia and metabolic limitations
· Effector cell survival in the tumor microenvironment
· Syngeneic, xenogeneic and humanized mouse models
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.